Therefore, in accordance with our data, cancer cells expressing the V225I mutant, or another mutation in the caspase-cleavage site of HuR, would have increased XIAP expression and thus have an increased likelihood of resistance to cancer therapy. This evidence concerns the gene XIAP and cancer.